PBD BIOTECH SECURES GRANT OF KEY PATENT.

 
FREE EXCERPT

PBD Biotech's key technology patent has been granted by the European Patent Office, covering its Actiphage technology that allows the sensitive and specific detection of live bacteria within six hours.

The phage-based technology is currently applied to the detection of mycobacterial diseases in animals - such as Bovine tuberculosis (TB) and Johne's disease and is also applicable to human infections, including other bacterial families.

Dr Berwyn Clarke, PBD Biotech's Chief Executive Officer, comments: The technology has already been successfully applied for analysis of blood and milk and, for the first time, gives a realistic alternative to culture but within 6 to 8 hours rather than many weeks.

Having the patent granted for the Actiphage Rapid technology is a major milestone for the company and allows us to confidently pursue our commercialisation plans in Europe and internationally.

Mycobacterial infection is responsible for several chronic diseases worldwide and existing diagnostics are limited by sensitivity, accuracy and speed of delivering reliable results.

Dr Clarke continues: Grant of the European patent strengthens our belief in the uniqueness of this test, and also ensures that investment in further development of this technology for other applications is safeguarded.

Earlier this year, the UK Government's Animal and Plant Health Agency (APHA) approved Actiphage for exceptional private use in farms where there is chronic infection of Bovine TB. This followed a successful on-farm demonstration, which used Actiphage to provide early identification of affected cows as part of a successful disease management strategy.

International trials are also underway in the USA and Canada, with additional discussions in other regions including the Europe and South America.

About PBD Biotech

PBD Biotech Limited specialises in the use of novel bacteriophage-based technology in the field of veterinary diagnostics. The company has developed proprietary technology that can be used to detect the presence of mycobacteria such as Mycobacterium bovis (bovine TB) and Mycobacterium avium subsp.paratuberculosis (MAP; Johne's Disease), which are significant causes of morbidity and loss of productivity in the agricultural industry. In addition, the technology has potential application in other bacterial systems

About Dr Berwyn Clarke

Dr Berwyn Clarke BSc, PhD is Chief Executive Officer and co-founder of PBD Biotech - which has developed Actiphage, a novel...

To continue reading

FREE SIGN UP